When it comes to healthcare stocks, many investors pay attention to the usual suspects: Eli Lilly, Novo Nordisk, CVS Health, or Johnson & Johnson. These companies have built up enormous brand equity ...

Minoxidil — commonly sold under the brand name Rogaine — is the only FDA-approved drug to treat both male and female pattern hair loss. But Shepherd said dosage and application varies due to hormonal ...

Both stocks have huge opportunities still in front of them. When it comes to investing, sometimes you want to take a big swing. After all, it's not always the number of winners in your portfolio that ...

What Happened? A number of stocks jumped in the afternoon session after the major indices rebounded (Nasdaq +1.5%, S&P 500 +1 ...

Hims and Hers stock rally looms with bullish EMAs, Novo Nordisk partnership, ZAVA acquisition, and new product launches ...

While some compounding pharmacies have stopped making alternatives to Wegovy and Zepbound since shortages were declared over, ...

As more CFOs step into the public spotlight by participating in events and conferences, the cost of misspeaking and the importance of leadership alignment on policy are increasing.

Discover why Hims & Hers is leading the telehealth market with strong growth, a loyal user base, and expansion into new ...

Salem Investment Counselors Inc. bought a new stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) during the 1st quarter, according to its most recent disclosure with the Securities ...

Eli Lilly found itself in a pharmaceutical pickle after its CFO claimed telehealth partners don’t compound key weight-loss ...

The renowned health and wellness platform, Hims & Hers Health, Inc. HIMS, has cemented its position as a leading ...

Eli Lilly will partner only with telehealth firms that agree to stop selling compound versions of its drug Zepbound or Novo Nordisk’s Wegovy, a move that sidelines Hims & Hers Health, Bloomberg ...